首页> 外文期刊>Cancer biology & therapy >L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.
【24h】

L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.

机译:L-肉碱通过调节肉碱棕榈酰转移酶的表达和活性来改善小鼠癌症恶病质。

获取原文
获取原文并翻译 | 示例
       

摘要

Cancer cachexia is characterized by progressive weight loss with the depletion of adipose tissue and skeletal muscle. Impaired fatty acid oxidation mainly resulting from the decrease of carnitine palmitoyltransferase I and II activities in the liver is an important factor that contributes to cancer cachexia . Although recent studies suggest a potential application of L-carnitine in treatment of cancer cachexia, the underlying mechanisms are unknown. In the present study, we aim to assess the effects of L-carnitine on the activity and expression of CPT I and II in the liver of cachectic cancer mice. Our results show that the inoculation of colon-26 adenocarcinoma cells into mice led to cancer cachexia characterized by notable decreases in food intake, gastrocnemius muscle and epididymus fat weight. In addition, the mRNA level and activity of liver carnitine palmitoyltransferase (CPT) I and II, and serum levels of free carnitine and acetylcarnitine were markedly decreased in cachectic mice, accompanied by marked increases in serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). A continuous oral treatment with L-carnitine at 18 mg/kg per day increased dietary uptake, gastrocnemius muscle weight and epididymus fat weight, increased blood glucose and serum albumin levels, and decreased total cholesterol level in cancer cachectic mice, but did not affect tumor growth. These effects of L-carnitine on cancer cachexia mice were accompanied by the upregulation of mRNA level of CPT I and II and increased enzyme activity of CPT I in the liver, as well as the downregulation of serum TNF-alpha and IL-6 levels. Moreover, free carnitine levels were negatively correlated with serum TNF-alpha or IL-6 level. These results indicate that L-carnitine ameliorates cancer cachexia by regulating serum TNF-alpha and IL-6 levels and modulating the expression and activity of CPT in the liver.
机译:癌症恶病质的特征是随着脂肪组织和骨骼肌的耗竭而逐渐减轻体重。脂肪酸氧化受损主要是由于肝脏中肉碱棕榈酰转移酶I和II活性的降低,是导致癌症恶病质的重要因素。尽管最近的研究表明左旋肉碱在癌症恶病质的治疗中有潜在的用途,但其潜在机制尚不清楚。在本研究中,我们旨在评估左旋肉碱对恶病质癌症小鼠肝脏中CPT I和II活性和表达的影响。我们的结果表明,向小鼠接种结肠26腺癌细胞会导致癌症恶病质,其特征是食物摄入量,腓肠肌和附睾脂肪重量显着减少。此外,恶病质小鼠的肝肉碱棕榈酰转移酶(CPT)I和II的mRNA水平和活性以及游离肉碱和乙酰肉碱的血清水平显着降低,同时血清肿瘤坏死因子-α(TNF- α)和白介素6(IL-6)。每天以18 mg / kg的L-肉碱连续口服治疗可增加饮食摄取,腓肠肌重量和附睾脂肪重量,血糖和血清白蛋白水平升高以及癌症恶病质小鼠的总胆固醇水平降低,但不影响肿瘤增长。 L-肉碱对癌症恶病质小鼠的这些作用伴随着CPT I和II mRNA水平的上调和肝脏中CPT I酶活性的增加,以及血清TNF-α和IL-6水平的下调。此外,游离肉碱水平与血清​​TNF-α或IL-6水平呈负相关。这些结果表明,L-肉碱可通过调节血清TNF-α和IL-6的含量,并调节肝脏中CPT的表达和活性来改善癌症恶病质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号